Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Biogen (BIIB) Price & Analysis

BIIB Stock Chart & Stats

$253.62$3.97(1.59%)
At close: 4:00 PM EDT
$200$225$2503 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
$251.19 - $258.73
52-Week Range
$146.52 - $258.78
Previous Close
$249.65
Volume
596.37K
Average Volume (3M)
1.30M
Market Cap
$37.49B
Enterprise Value
$39.88B
Total Cash (Recent Filing)
$1.30B
Total Debt (Recent Filing)
$7.80B
Price to Earnings (P/E)
107.5
Beta
0.43
Next Earnings
Feb 17, 2027
EPS Estimate
2.86
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Growth Portfolio Momentum

Rapid growth in the newer portfolio is reducing reliance on Biogen’s legacy MS franchise and broadening its revenue base. The portfolio’s increasing contribution supports a more durable return to growth, provided adoption remains strong across its neurological and specialty products.

Pipeline Diversification

A diversified late-stage pipeline gives Biogen several opportunities to replenish or expand its product portfolio rather than depending on one therapeutic area. Multiple registrational programs can improve long-term growth resilience if clinical and regulatory outcomes support commercialization.

Cash Generation

Substantial operating and free cash flow indicates that Biogen’s earnings remain meaningfully supported by internally generated cash. This provides capacity to fund research, launch products, pursue business development, and reduce debt while maintaining strategic flexibility.

Bears Say

Profitability Compression

The sharp decline in operating and net margins weakens earnings durability even though revenue is growing modestly. Lower profitability reduces the cash available per dollar of sales and can constrain investment capacity if higher launch and development spending persists.

VUMERITY Formulary Pressure

Formulary changes are pressuring an established product and demonstrate Biogen’s exposure to payer-driven access and reimbursement decisions. Continued pressure on VUMERITY can weigh on the legacy portfolio and require growth products to offset erosion in recurring revenue.

Acquisition-Related Debt

The post-acquisition debt burden creates a continuing call on future cash flow, even though management plans repayment by the end of 2027. Debt reduction may compete with research, launches, or additional business development if operating conditions weaken.

Biogen News

BIIB FAQ

What was Biogen’s price range in the past 12 months?
Biogen lowest stock price was $146.52 and its highest was $258.78 in the past 12 months.
What is Biogen’s market cap?
Biogen’s market cap is $37.49B.
When is Biogen’s upcoming earnings report date?
Biogen’s upcoming earnings report date is Feb 17, 2027 which is in 108 days.
How were Biogen’s earnings last quarter?
Biogen released its earnings results on Oct 28, 2026. The company reported $2.62 earnings per share for the quarter, beating the consensus estimate of $1.992 by $0.628.
Is Biogen overvalued?
According to Wall Street analysts Biogen’s price is currently Undervalued.
Does Biogen pay dividends?
Biogen does not currently pay dividends.
What is Biogen’s EPS estimate?
Biogen’s EPS estimate is 2.86.
How many shares outstanding does Biogen have?
Biogen has 147,820,220 shares outstanding.
What happened to Biogen’s price movement after its last earnings report?
Biogen reported an EPS of $2.62 in its last earnings report, beating expectations of $1.992. Following the earnings report the stock price went down -3.434%.
Which hedge fund is a major shareholder of Biogen?
Currently, no hedge funds are holding shares in BIIB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology